GlassScriptPhysician profile
Aprill M Rambarran
NPI 1609003177
$13,832.00
in general payments reported to CMS, 2019-2025
60 companies · $767 in 2025
The $767 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,713 · 2020: $1,661 · 2021: $2,823 · 2022: $2,324 · 2023: $2,451 · 2024: $2,093 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,277 · Education: $33.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,277.19 |
| Education | $33.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,033.36 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,298.97 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,133.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $956.49 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $724.33 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $639.96 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $538.81 | 2021-2025 | |
| Corium, LLC | $447.04 | 2022-2024 | Azstarys |
| Eisai INC. | $384.11 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $368.70 | 2019-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $336.88 | 2019-2024 | Belsomra, Steglatro, Vaxneuvance |
| Supernus Pharmaceuticals, INC. | $297.82 | 2020-2024 | Qelbree, Qelbree, Tlando |
| Otsuka America Pharmaceutical, INC. | $282.11 | 2022-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $275.31 | 2019-2024 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $254.68 | 2019-2023 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aprill Rambarran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.